Hot Pursuit     15-Jan-25
Alembic Pharma receives USFDA nod for Brexpiprazole tablets
Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brexpiprazole Tablets.
Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, and also used in treatment of schizophrenia in adults and pediatric patients ages 13 years and older. Refer label for a detailed indication.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, of Otsuka Pharmaceutical Company (Otsuka).

Brexpiprazole tablets have an estimated market size of $ 2 billion for twelve months ending September 2024 according to IQVIA.

Alembic has a cumulative total of 220 ANDA approvals (194 final approvals and 26 tentative approvals) from USFDA.

Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients.

The pharmaceutical company’s consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024.

The scrip shed 0.44% to currently trade at Rs 1,004.75 on the BSE.

Previous News
  Alembic Pharmaceuticals consolidated net profit rises 12.34% in the September 2024 quarter
 ( Results - Announcements 07-Nov-24   14:16 )
  Market near day's high; metal shares rally for 3rd day
 ( Market Commentary - Mid-Session 01-Jul-24   12:34 )
  Volumes soar at Aditya Birla Fashion & Retail Ltd counter
 ( Hot Pursuit - 08-May-23   14:30 )
  Alembic Pharma's oncology formulations unit successfully completes USFDA inspection
 ( Corporate News - 09-Oct-24   09:16 )
  Alembic Pharma gets PAS nod from USFDA for pregabalin capsules
 ( Hot Pursuit - 22-Dec-22   14:57 )
  Alembic Pharmaceuticals receives USFDA approval for Acitretin Capsules
 ( Corporate News - 07-Aug-24   18:11 )
  Alembic Pharma gets USFDA nod for Doxycycline Capsules
 ( Hot Pursuit - 28-Jun-24   12:20 )
  Alembic Pharmaceuticals receives USFDA tentative approval for Bosutinib tablets
 ( Corporate News - 01-Jul-24   10:44 )
  Alembic Pharmaceuticals spurts on USFDA nod for Dabigatran Etexilate capsules
 ( Hot Pursuit - 07-Apr-22   11:47 )
  Alembic Pharma receives PAS approval for its sANDA Pregabalin Capsules
 ( Corporate News - 22-Dec-22   13:53 )
  Alembic Pharmaceuticals receives USFDA approval for Clarithromycin Tablets
 ( Corporate News - 01-Feb-22   10:52 )
Other Stories
  Bharti Airtel records multi-fold jump in Q3 PAT to Rs 16,135 cr; ARPU rises to Rs 245
  06-Feb-25   18:03
  KPI Green Energy hits the roof after Q3 PAT zooms 67% YoY to Rs 85 cr
  06-Feb-25   16:00
  REC Q3 PAT climbs 23% YoY to Rs 4,076 cr; declares dividend of Rs 4.30/sh
  06-Feb-25   16:00
  Enviro Infra spurts after Q3 PAT soars to Rs 37 cr
  06-Feb-25   15:49
  NMDC Q3 PAT climbs 29% YoY to Rs 1,897 cr
  06-Feb-25   15:12
  SBI Q3 PAT climbs 84% YoY to Rs 16,891 crore in FY25
  06-Feb-25   15:05
  Mahanagar Telephone Nigam Ltd leads losers in 'A' group
  06-Feb-25   15:00
  BEML slides as Q3 PAT tumbles 49% YoY to Rs 24 cr
  06-Feb-25   14:50
  Shivalik Rasayan Ltd leads losers in 'B' group
  06-Feb-25   14:45
  Trent Q3 PAT grows 34% YoY to Rs 497 crore
  06-Feb-25   14:43
Back Top